二甲双胍对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪含量的影响  

Liver fat contents in type 2 diabetic patients with nonalcoholic fatty liver disease under metformin treatment

作　　者：赵邦凤[1] 吴国亭[1] 

机构地区：[1]同济大学附属第十人民医院内分泌科,上海200072

出　　处：《同济大学学报（医学版）》2012年第5期58-61,共4页Journal of Tongji University(Medical Science)

摘　　要：目的探讨二甲双胍治疗对2型糖尿病(type 2 diabetes mellitus,T2DM)合并非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD)患者肝脏脂肪含量变化的影响。方法采用磁共振波成像技术(magneticresonance spectroscopy,MRS)定量检测肝脏脂肪含量,脂峰下面积/(脂峰下面积+水峰下面积)大于5.5%认为具有脂肪肝。将T2DM合并NAFLD分为二甲双胍治疗组(A组,24例)和无二甲双胍治疗组(B组,24例),分析二甲双胍治疗T2DM合并NAFLD肝脏脂肪含量的变化,同时分析NAFLD患者的相关危险因素及临床特点。结果经二甲双胍治疗后,与B组相比,A组肝脏脂肪的含量有减少趋势,但差异无统计学意义(P>0.05);A组患者WC、BMI、FPG、HbA1c、TG明显减少,差异有统计学意义(P<0.05),AST、ALT等无明显变化(P>0.05)。结论二甲双胍不仅能改善T2DM合并NAFLD的糖代谢,还可以减少肝脏脂肪含量。Objective To investigate the change of liver fat contents in type 2 diabetic patients with non-alcoholic fatty liver disease （NAFLD）. under metformin treatment. Methods Fifty patients with type 2 diabetes mellitus （T2DM） and NAFLD were assigned to receive metformin treatment （ groupA, n = 25） or non-metformin treatment （group B, n = 25 ）. The intrahepatic fat contents were examined by MRS ; the mass of fat peak/the mass of fat peak ＋ the mass of water peak 〉 5.5 % was diagnosed as NAFLD. Results Twenty four cases in each group were completed with treatment and followed up. There were no significant differences in liver fat accumulation between two groups （ P 〉 0.05 ） ; however, after treatment the TC, BMI, FPG, HbA1 c and TG levels in group A were significantly lower than those in group B. Conclusion Metformin can improve glycometabolism in T2DM patients with NAFLD.

关 键 词：2型糖尿病 非酒精性脂肪肝 二甲双胍 内脏脂肪 

分 类 号：R587.1[医药卫生—内分泌]